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Abstract
Background: Doubts remain over the use of the ECG in identifying those with increased left
ventricular (LV) mass. This is especially so in young individuals, despite their high prevalence of ECG
criteria for LV hypertrophy. We performed a study using cardiovascular magnetic resonance
(CMR), which provides an in vivo non-invasive gold standard method of measuring LV mass, allowing
accurate assessment of electrocardiography as a tool for defining LV hypertrophy in the young.
Methods and results: Standard 12-lead ECGs were obtained from 101 Caucasian male army
recruits aged (mean ± SEM) 19.7 ± 0.2 years. LV mass was measured using CMR. LV mass indexed
to body surface area demonstrated no significant correlation with the Cornell Amplitude criteria
or Cornell Product for LV hypertrophy. Moderate correlations were seen with the Sokolow-Lyon
Amplitude (0.28) and Sokolow-Lyon Product (0.284). Defining LV hypertrophy as a body surface
area indexed left ventricular mass of 93 g/m2, calculated sensitivities [and specificities] were as
follows; 38.7% [74.3%] for the Sokolow-Lyon criteria, 43.4% [61.4%] for the Sokolow-Lyon
Product, 19.4% [91.4%] for Cornell Amplitude, and 22.6% [85.7%] for Cornell Product. These
values are substantially less than those reported for older age groups.
Conclusion: ECG criteria for LV hypertrophy may have little value in determining LV mass or the
presence of LV hypertrophy in young fit males.
Background
Cardiovascular risk rises with increasing left ventricular
(LV) mass [1], with dichotomously-defined LV hypertro-
phy a powerful and independent risk factor in a variety of
disease states [2-4], and even amongst the healthy and
normotensive [1,5]. Electrocardiography (ECG) has been
used to help identify increased LV mass and thus cardio-
vascular risk[6,7]. However, doubts remain over the sensi-
tivity and, increasingly, specificity of the ECG in
identifying those with increased LV mass [6,8], especially
in younger individuals [9-11]. Indeed, in 300 healthy
post-pubertal boys (mean age 16 years) with a sedentary
lifestyle, 23% fulfilled the Sokolow-Lyon Amplitude crite-
ria for LV hypertrophy [10].
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In an effort to resolve these issues, attempts have been
made to define the sensitivity and specificity of ECG crite-
ria in identifying LV hypertrophy, by comparison with
echocardiographic estimates of LV mass [12-16]. How-
ever, few have attempted to address this issue in the young
and fit [11,17]. Further, when applied to the individual,
echocardiographic measures of LV mass are imprecise as
they assume a uniform LV shape and apply a cubing
mathematical formula to derive an estimation of LV mass.
The advent of cardiovascular magnetic resonance (CMR)
now offers a gold standard in the accurate quantification
of LV mass [18], and studies confirm the weakness of
echocardiography in this regard [19]. For this reason,
CMR has been used to assess the validity of ECG-derived
indices of LV mass; but to date, only in small cohorts of
older adults [20,21].
Thus, we have used CMR to clarify whether the high prev-
alence of ECG-defined LV hypertrophy in the young truly
represents the prevalence of LV hypertrophy. We have
assessed four different criteria: the Sokolow-Lyon Ampli-
tude [22], Cornell Amplitude[23], Sokolow-Lyon Product
and Cornell Product [24] in diagnosing LV hypertrophy in
a large sample of young male army recruits.
Methods
This study complies with the Declaration of Helsinki and
had appropriate ethics approval (Defence Medical Serv-
ices Clinical Research Committee). Written informed con-
sent was obtained from all participants.
Study subjects
Subjects were enrolled in the LARGE Heart study,
described in detail elsewhere [25]. In brief, consecutive
healthy young Caucasian male army recruits were studied
at entry to the Army Training Regiment, Lichfield, United
Kingdom between July 2002 and April 2004. Any poten-
tial subjects with hypertension or regular medication use
were excluded prior to the start of the study. Subject
height and weight were recorded and body surface area
(BSA) estimated using the Dubois formula: BSA =
0.20247 × height (m)0.725 × weight (Kg)0.425. LV mass was
quantified using CMR, and standard resting 12-lead elec-
trocardiography was performed.
CMR assessment of LV mass
Imaging was performed using a mobile 1.5 Tesla Siemens
Sonata CMR scanner applying protocols previously
described [26]. In brief, the LV short axis was identified by
first piloting a vertical long axis (VLA) plane from the
transaxial plane. The horizontal long axis (HLA) plane
was imaged, and from this a stack of short axis (SA)
images was obtained during breath-holding, covering the
length of the LV. ECG-gated cine images were used in
order to measure the LV mass at end-diastole. The tempo-
ral resolution was 21.6 ms. The in plane pixel size was 2.1
× 1.3 mm. All images were acquired using a steady state
free precession (SSFP) sequence. Image analysis was per-
formed by one investigator (JP) blind to other study data,
using CMRtools (Cardiovascular Imaging Solutions, Lon-
don, UK). The area of myocardium was calculated for each
SA slice and, using Simpson's method, LV myocardial vol-
ume calculated. Trabeculae were included in the assess-
ment of LV mass, but papillary muscles were excluded.
This volume was then multiplied by myocardial tissue
specific density (1.05 g/cm3). LV mass indexed to BSA was
used in statistical analysis. All measurements of LV mass
presented here were before a period of physical training
and have been presented previously [25].
Electrocardiography
Electrocardiographic assessment was performed immedi-
ately prior to scanning in a randomly-selected subgroup
of individuals. A standard resting 12-lead recording was
made during quiet respiration, with subjects in a supine
position. The ECG was recorded at 25 mm/s and 0.1 mV/
mm standardisation with a MAC 5000 resting ECG system
(GE Medical Systems, UK). All ECG characteristics were
determined from digital data using an appropriate soft-
ware package (Cardiosoft, GE Medical Systems). From
these measurements, one observer blinded to CMR data
calculated 4 ECG criteria: Sokolow-Lyon Amplitude [22],
Sokolow-Lyon Product [24], Cornell Amplitude [27] and
Cornell Product [24]. LV hypertrophy was defined as a
Sokolow-Lyon Amplitude of [SV1 + RV5 or RV6] ≥ 35 mm;
a Sokolow-Lyon Product of [(SV1 + RV5) or (RV6) × QRS
duration] ≥ 2940 mm·ms [20]; a Cornell Amplitude of
[RaVL + SV3] ≥ 28 mm and a Cornell Product of [(RaVL +
SV3) × QRS duration] ≥ 2440 mm·ms.
Statistical analysis
Data were analysed using SPSS software (version 12.0.1).
The relationship between LV mass indexed to BSA
(indexed LV mass) and Sokolow-Lyon Amplitude,
Sokolow-Lyon Product, Cornell Amplitude, and Cornell
Product were assessed using Pearson's correlation coeffi-
cients. To assess the performance of different ECG criteria,
LV hypertrophy was defined using three different criteria:
The lowest threshold limit for 'acceptable' LV mass in this
study was one defined using CMR in a study of 30 normal
men, albeit of greater age (20–65 years) this being ≤  83 g/
m2 [20,28]. However, 63% of our subjects had values of
indexed LV mass greater than this. As a result, we studied
two other thresholds; the first being 2 standard deviations
(SD) above the mean for our group of subjects (108 g/
m2). The other was based on a study that tried to define
normal ranges according to age ranges. The lowest age
range for males in that study was 20–29 and gave a cut off
value of 93 g/m2 2-SD above the mean [29]. Sensitivities
and specificities for the existing cut off values for theJournal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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Sokolow-Lyon Amplitude, Sokolow-Lyon Product, Cor-
nell Amplitude, and Cornell Product were calculated for
each of the three cut off values of LV hypertrophy. Per-
formance of the different ECG criteria over the full range
of amplitudes was assessed using receiver operator curve
(ROC) characteristics. Curves were constructed using the
three different cut off values for LV hypertrophy. Signifi-
cance tests were performed to assess the difference
between the area under the curve for the ROC curve and
the area under the line of no discrimination (0.5). The
mean indexed LV mass of the participants with and with-
out ECG-defined LV hypertrophy were compared using an
unpaired sample t-test.
Results
One hundred and one subjects were enrolled, whose
(mean ± SD) age was 19.7 ± 2.3 years, height 178.4 + 7.0
cm, weight 73.6 ± 9.8 kg, systolic blood pressure 122.1 ±
16.9 mm Hg, diastolic blood pressure 68.4 ± 10.5 mm Hg,
LV mass 168.0 ± 24.9 g and LV mass indexed to BSA 87.7
± 10.3 g/m2. Prevalence of ECG-defined LV hypertrophy
was 29.7%, 41.6%, 11.9% and 16.8% for Sokolow-Lyon
Amplitude, Sokolow-Lyon Product, Cornell Amplitude
and Cornell Product criteria respectively.
We assessed the correlation of Sokolow-Lyon Amplitude,
Sokolow-Lyon Product, Cornell Amplitude and Cornell
Product with LV mass index (Table 1). A significant asso-
ciation was only demonstrable with the Sokolow-Lyon
Amplitude and Product (R = 0.280 and 0.284 respec-
tively).
Sensitivity and specificity of the four ECG criteria in iden-
tifying CMR-determined LV hypertrophy was then
addressed using 83 g/m2 as a threshold for LV hypertrophy
(Table 2). All four ECG criteria demonstrate low sensitiv-
ity (14.1% to 43.8%) with variable specificities (62.2% to
91.9%). The sensitivity of these criteria is not impressive
at the threshold of 93 g/m2 (sensitivity from 19.4% to
43.4% and specificity from 61.4% to 91.4%). On moving
the threshold up to 108 g/m2, sensitivity improves (up to
75% for the Sokolow-Lyon criteria) with a further fall in
specificity (59.8% to 88.7%). The prevalence of LV hyper-
trophy for the cut off values was 63% at 83 g/m2, 31% at
93 g/m2, and 4% at 108 g/m2. ROC curves for the
Sokolow-Lyon criteria were constructed using the three
different cut off values for LV hypertrophy (Figures 1, 2
and 3). There was no statistically significant difference
between the area under the curve for any of the amplitude
criteria and the line of no discrimination (Table 3).
Finally, we calculated the mean LV mass index for those
subjects categorised as having or lacking LV hypertrophy
as defined by each of the four ECG criteria (Table 4). Only
using the Sokolow-Lyon Amplitude was there a significant
difference in LV mass index between ECG positive and
ECG negative.
Discussion
This is the first study to examine the validity of electrocar-
diography in the determination of LV hypertrophy in
young healthy males, using CMR-measured (as opposed
to echocardiographically-imputed) LV mass as the gold-
standard. It demonstrates the poor sensitivity of estab-
lished ECG criteria in identifying LV hypertrophy in such
individuals.
Our data confirm the high incidence of electrocardio-
graphically-defined LV hypertrophy amongst the young
and healthy. Twenty-nine percent had LV hypertrophy as
defined by Sokolow-Lyon ECG Amplitude criteria, a figure
similar to the 23% incidence previously observed in
healthy teenage non-athletes [10]. One would expect the
incidence of physiological left ventricular hypertrophy to
be higher in this cohort as army recruits will be more ath-
letic than the general population. Other studies have
showed a higher prevalence of ECG defined left ventricu-
lar hypertrophy in the athletic rising to 50% amongst 172
teenage soccer players [11], and 45% amongst 1000 teen-
age elite athletes [10].
The amplitude criteria assessed here were all derived using
various markers to indicate LV hypertrophy, but all in
older age groups, and before the advent of CMR. Echocar-
diography or autopsy were used to define or validate the
criteria tested here, and in the case of the Sokolow Lyon,
Table 1: Correlation with LV mass indexed to BSA
Criteria Pearson Correlation Coefficient P-value
Sokolow-Lyon Amplitude
(mm)
0.280 0.005
Sokolow-Lyon Product
(mm·ms)
0.284 0.004
Cornell Amplitude
(mm)
0.065 0.516
Cornell Product
(mm·ms)
0.097 0.336Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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the criteria were based on clinical features predominantly
[30]. Most of the subjects in these validation studies
would have had pathological LV hypertrophy, unlike in
this study.
The CMR data presented here shows some striking differ-
ences to the validation studies, and other studies assessing
ECG criteria for LV hypertrophy. Across a range of past
studies and methods, we see generally poor sensitivities,
but relatively good specificities, with correlation coeffi-
cients clustering between 0.5 and 0.6, but these have all
been done in older subjects, many of whom have estab-
lished cardiac pathology [23,27,24,11,16]. The correla-
tion coefficients are much weaker in this cohort despite
similar sample sizes to older studies. Only the Sokolow-
Lyon Amplitude and Product show a significant correla-
tion with indexed LV mass, and even this is weak. No rela-
tionship is seen with the Cornell Amplitude or Cornell
Product. This implies that in a population of young fit
males, existing ECG amplitude criteria do little to indicate
LV mass. Of the existing amplitude criteria, the Sokolow-
Lyon Amplitude and Product may give some indication of
LV mass, but much less so than in a group of older adults
with other evidence of underlying cardiac disease. It is
unclear why the Sokolow Lyon criteria should show a
stronger relationship in the young to the Cornell criteria.
There is likely to be a feature in this younger cohort which
diminish the use of the Cornell criteria, such as body habi-
tus. The BSA measurements confirm that the individuals
in this study are very thin chested which would impact on
the specificity of some of the ECG criteria. One could
speculate that the Cornell criteria are better at detecting
pathological left ventricular hypertrophy rather than
physiological hypertrophy which is likely to be the pre-
dominant form in this group and hence these results.
According to these results, while the Sokolow Lyon criteria
may give some indication of LV mass, they are not likely
to demonstrate whether this is pathological, and is
unlikely to be of any clinical use in this age group.
Some recent studies have tried to establish normal ranges
for LV mass stratified by age group and sex. The cut off
used in this study used an indexed LV mass cut off of 83
ROC curves with a cut off value of 83 g/m2 for LV hypertro- phy Figure 1
ROC curves with a cut off value of 83 g/m2 for LV 
hypertrophy.
ROC curves with a cut off value of 93 g/m2 for LV hypertro- phy Figure 2
ROC curves with a cut off value of 93 g/m2 for LV 
hypertrophy.
ROC curves with a cut off value of 108 g/m2 for LV hypertro- phy Figure 3
ROC curves with a cut off value of 108 g/m2 for LV 
hypertrophy.Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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g/m2, based on a study of 60 men with a mean age of 43
years[28]. A more recent study has tried to define indexed
LV mass values using SSFP CMR stratified by age and sex
[29]. In this study an upper limit of 93 g/m2 is inferred for
men aged 20–29. This was based on a value 2 standard
deviations (SD) above the mean from a sample of 10 men
aged 20–29 years. That study did not include those aged
under 20 years, the age of many of the participants in our
report but for the purposes of this study provided a rea-
sonable approximation. Unfortunately most of these esti-
mates are based on small cohorts. In this cohort, the value
2-SD above the upper limit of normal was 108 g/m2,
which is much higher than either of the quoted figures.
Participants in this study are army recruits and may be
more active than their peers, so this higher cut off may
represent an element of physiological LV hypertrophy
seen in athletes [11,17]. In fact in the analysis, there was
little evidence of pathological forms of LV hypertrophy
such as hypertrophic cardiomyopathy, so most of the
increased LV mass is likely to be physiological in this
cohort.
Despite the absence of an established mass cut off in this
age group, across the three mass cut-offs for LV hypertro-
phy, the ROC curves demonstrate that all the ECG criteria
are poor at delineating LV hypertrophy. One pays the
price either with sensitivity or specificity over a range of
amplitudes. With none of the cut off values for indexed LV
mass was there a statistically significant difference
between the line of no discrimination.
We did show that participants who were Sokolow-Lyon
Amplitude positive for LV hypertrophy did have a higher
LV mass, but this is not surprising considering the slight
positive correlation between indexed LV mass and
Sokolow-Lyon Amplitude. This must, however, be inter-
preted in the context of the ROC curves for these criteria,
which imply there is little practical use for the Sokolow-
Lyon Amplitude in the diagnosis of LV hypertrophy in the
young.
There are a number of strengths to this study. It has used
CMR rather than echocardiography to determine LV mass.
It has used this gold standard to validate and assess these
commonly used ECG criteria in population of fit young
males unlike the majority of previous work, which has
been in an older population, who often have disease.
There are, however, some limitations. The sample is rela-
tively small, and the subjects are all male. It is difficult to
perform such a study when there is no well-established
cut off for normal LV mass in young males. This became
particularly apparent when analysing the participants
who had an LV mass 2 SD above the mean for this group
where only four subjects were present. In such a popula-
tion increased LV mass in itself may be marker of health
rather than disease. The population is white and does not
account for racial differences [31].
To conclude, commonly used amplitude criteria may have
little practical use in detecting LV hypertrophy in the
young. In particular, Cornell Amplitude and Cornell
Product have little relationship with LV mass in a group of
Table 2: Sensitivities and specificities according to three partitions values of LV mass indexed to BSA (sens = sensitivity, spec = 
specificity).
LV mass indexed to BSA partition values
83 g/m2 93 g/m2 108 g/m2
ECG Criteria Sens
(%)
Spec
(%)
Sens
(%)
Spec
(%)
Sens
(%)
Spec
(%)
Sokolow-Lyon Amplitude
>35 mm
35.9 81.1 38.7 74.3 50.0 71.1
Sokolow-Lyon Product
>2940 mm·ms
43.8 62.2 43.4 61.4 75.0 59.8
Cornell Amplitude
>28 mm
14.1 91.9 19.4 91.4 25.0 88.7
Cornell Product
>2440 mm·ms
18.8 86.5 22.6 85.7 25.0 83.5
Table 3: Area under curve values from ROC curve analysis.
Area Under Curve (significance)
LVH Cut off Value: 83 g/m2 93 g/m2 108 g/m2
Sokolow-Lyon Amplitude 0.592 (0.13) 0.613 (0.07) 0.722 (0.13)
Sokolow-Lyon Product 0.610 (0.07) 0.618 (0.06) 0.678 (0.23)
Cornell Amplitude 0.494 (0.92) 0.524 (0.71) 0.469 (0.83)
Cornell Product 0.514 (0.81) 0.533 (0.60) 0.454 (0.75)Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
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young males. Whilst the Sokolow-Lyon Amplitude has a
(weak) correlation with LV mass, the price is paid in terms
of specificity and sensitivity when more stringent criteria
defining LVH are applied.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HEM and JRP conceived the study. JRP collected electro-
cardiographic data with support from MW. Numerical
data were extracted and analysed by SMAS and RS. DP
oversaw MRI acquisition and analysis. All authors contrib-
uted to the preparation of the manuscript, and read and
approved the final manuscript.
Acknowledgements
The LARGE Heart study was primarily funded by a British Heart Foundation 
Project Grant (PG/02/021) and an unconditional educational grant from 
Aventis UK. JRP (PG/02/021) was funded by the British Heart Foundation 
which also provides core funding for the Centre for Cardiovascular Genet-
ics. The CMR Unit at Royal Brompton Hospital receives research support 
from CORDA, Siemens and the British Heart Foundation. HM was funded 
by the Portex Endowment at the Institute of Child Health, London.
The authors would like to thank the army recruit volunteers at Lichfield, 
the hospitality and co-operation of the staff at the Army Training Regiment 
Lichfield particularly the staff of the Medical Reception Station, the staff of 
the Officer's Mess and the commanding officer.
The authors would like to thank Alliance Medical Limited, who provided 
the mobile scanner, and especially recognise the hard work of the scanning 
technicians and to Professor S Humphries from the BHF laboratories at 
UCL for his contribution to this project.
This study was supported by unconditional educational grant from Aventis 
UK.
References
1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognos-
tic implications of echocardiographically determined left
ventricular mass in the Framingham Heart Study.  N Engl J
Med 1990, 322:1561-1566.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation
of left ventricular mass and geometry to morbidity and mor-
tality in uncomplicated essential hypertension.  Ann Intern Med
1991, 114:345-352.
3. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS: The
prognostic role of left ventricular hypertrophy in patients
with or without coronary artery disease.  Ann Intern Med 1992,
117:831-836.
4. Bolognese L, Dellavesa P, Rossi L, Sarasso G, Bongo AS, Scianaro MC:
Prognostic value of left ventricular mass in uncomplicated
acute myocardial infarction and one-vessel coronary artery
disease.  Am J Cardiol 1994, 73:1-5.
5. Post WS, Levy D: New developments in the epidemiology of
left ventricular hypertrophy.  Curr Opin Cardiol 1994, 9:534-541.
6. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli
WP: Determinants of sensitivity and specificity of electrocar-
diographic criteria for left ventricular hypertrophy.  Circulation
1990, 81:815-820.
7. Messerli FH, Aepfelbacher FC: Hypertension and left-ventricular
hypertrophy.  Cardiol Clin 1995, 13:549-557.
8. Devereux RB, Koren MJ, de SG, Okin PM, Kligfield P: Methods for
detection of left ventricular hypertrophy: application to
hypertensive heart disease.  Eur Heart J 1993, 14(Suppl D):8-15.
9. Edhouse J, Thakur RK, Khalil JM: ABC of clinical electrocardiog-
raphy. Conditions affecting the left side of the heart.  BMJ
2002, 324:1264-1267.
10. Sharma S, Whyte G, Elliott P, Padula M, Kaushal R, Mahon N, McK-
enna WJ: Electrocardiographic changes in 1000 highly trained
junior elite athletes.  Br J Sports Med 1999, 33:319-324.
11. Somauroo JD, Pyatt JR, Jackson M, Perry RA, Ramsdale DR: An
echocardiographic assessment of cardiac morphology and
common ECG findings in teenage professional soccer play-
ers: reference ranges for use in screening.  Heart 2001,
85:649-654.
12. Gasperin CA, Germiniani H, Facin CR, Souza AM, Cunha CL: An
analysis of electrocardiographic criteria for determining left
ventricular hypertrophy.  Arq Bras Cardiol 2002, 78:59-82.
13. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I,
Battistelli M, Bartoccini C, Porcellati C: Improved electrocardio-
graphic diagnosis of left ventricular hypertrophy.  Am J Cardiol
1994, 74:714-719.
14. Norman JE Jr, Levy D: Improved electrocardiographic detec-
tion of echocardiographic left ventricular hypertrophy:
results of a correlated data base approach.  J Am Coll Cardiol
1995, 26:1022-1029.
Table 4: Mean LV mass index for subjects categorized as having or lacking LV hypertrophy (LVH).
LV mass indexed to BSA (g/m2)
Mean ± SD (n)
Criteria ECG: No LVH ECG: LVH P-value
Sokolow-Lyon Amplitude
>35 mm
86.2 ± 9.9
(71)
91.3 ± 10.4
(30)
0.023
Sokolow-Lyon Product
>2940 mm·ms
86.4 ± 9.5
(59)
89.6 ± 11.1
(42)
0.126
Cornell Amplitude
>28 mm
87.1 ± 10.1
(89)
92.4 ± 10.5
(12)
0.092
Cornell Product
>2440 mm·ms
87.2 ± 10.2
(84)
90.3 ± 10.3
(17)
0.250Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Cardiovascular Magnetic Resonance 2009, 11:2 http://www.jcmr-online.com/content/11/1/2
Page 7 of 7
(page number not for citation purposes)
15. Norman JE Jr, Levy D, Campbell G, Bailey JJ: Improved detection
of echocardiographic left ventricular hypertrophy using a
new electrocardiographic algorithm.  J Am Coll Cardiol 1993,
21:1680-1686.
16. Okin PM, Roman MJ, Devereux RB, Kligfield P: Electrocardio-
graphic identification of increased left ventricular mass by
simple voltage-duration products.  J Am Coll Cardiol 1995,
25:417-423.
17. Raskoff WJ, Goldman S, Cohn K: The "athletic heart". Preva-
lence and physiological significance of left ventricular
enlargement in distance runners.  JAMA 1976, 236:158-162.
18. Myerson SG, Bellenger NG, Pennell DJ: Assessment of left ven-
tricular mass by cardiovascular magnetic resonance.  Hyper-
tension 2002, 39:750-755.
19. ellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pen-
nell DJ: Comparison of left ventricular ejection fraction and
volumes in heart failure by echocardiography, radionuclide
ventriculography and cardiovascular magnetic resonance;
are they interchangeable?  Eur Heart J 2000, 21:1387-1396.
20. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M:
New gender-specific partition values for ECG criteria of left
ventricular hypertrophy: recalibration against cardiac MRI.
Hypertension 2004, 44:175-179.
21. Carlsson MB, Trägårdh E, Engblom H, Hedström E, Wagner G, Pahlm
O, Arheden H: Left ventricular mass by 12-lead electrocardio-
gram in healthy subjects: comparison to cardiac magnetic
resonance imaging.  J Electrocardiol 2006, 39:67-72.
22. Sokolow M, Lyon TP: The ventricular complex in left ventricu-
lar hypertrophy as obtained by unipolar precordial and limb
leads. 1949.  Ann Noninvasive Electrocardiol 2001, 6:343-368.
23. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaud-
hary BS, Phillips MC: Electrocardiographic detection of left ven-
tricular hypertrophy: development and prospective
validation of improved criteria.  J Am Coll Cardiol 1985, 6:572-580.
24. Molloy TJ, Okin PM, Devereux RB, Kligfield P: Electrocardio-
graphic detection of left ventricular hypertrophy by the sim-
ple QRS voltage-duration product.  J Am Coll Cardiol 1992,
20:1180-1186.
25. Payne JR, Eleftheriou KI, James LE, Hawe E, Mann J, Stronge A,
Kotwinski P, World M, Humphries SE, Pennell DJ, Montgomery HE:
Left ventricular growth response to exercise and cigarette
smoking: data from LARGE Heart.  Heart 2006, 92:1784-1788.
26. Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduc-
tion in sample size for studies of remodeling in heart failure
by the use of cardiovascular magnetic resonance.  J Cardiovasc
Magn Reson 2000, 2:271-278.
27. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P:
Improved sex-specific criteria of left ventricular hypertrophy
for clinical and computer interpretation of electrocardio-
grams: validation with autopsy findings.  Circulation 1987,
75:565-572.
28. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU:
Normal human left and right ventricular dimensions for MRI
as assessed by turbo gradient echo and steady-state free pre-
cession imaging sequences.  J Magn Reson Imaging 2003,
17:323-329.
29. Maceira AM, Prasad SK, Khan M, Pennell DJ: Normalized left ven-
tricular systolic and diastolic function by steady state free
precession cardiovascular magnetic resonance.  J Cardiovasc
Magn Reson 2006, 8:417-426.
30. Sokolow M, Freidlander RD: The normal unipolar precordial
and limb lead electrocardiogram.  Am Heart J 1949, 38:665-687.
31. Rautaharju PM, Park LP, Gottdiener JS, Siscovick D, Boineau R, Smith
V, Powe NR: Race- and sex-specific ECG models for left ven-
tricular mass in older populations. Factors influencing over-
estimation of left ventricular hypertrophy prevalence by
ECG criteria in African-Americans.  J Electrocardiol 2000,
33:205-218.